You are here

Targeted Near-infrared Fluorescent Probes for Detection of Ovarian Cancer Lesions

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA126017-01A2
Agency Tracking Number: CA126017
Amount: $193,778.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: 2007
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PHYSICAL SCIENCES INC 20 NEW ENGLAND BUSINESS CENTER
ANDOVER, MA 01810
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANTON CHESTUKHIN
 (978) 689-0003
 chestukhin@psicorp.com
Business Contact
 DAVID WEATHERBY
Phone: (978) 689-0003
Email: weatherby@psicorp.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Ovarian Cancer (OC) is one of the deadliest gynecological cancers. The current screening approach for OC detection relies on measuring the blood level of ovarian cancer-specific antigen CA125, the only OC marker that is approved for clinical use. The strategy for OC management includes a combination of surgical treatment with chemotherapy regimens. Detection of primary and secondary OC lesions is very important for early diagnosis and effective surgical treatment. We propose to develop a novel class of targeted fluorescent probes that will specifically recognize tumor markers on the surface of OC cells. We will use near infrared (NIR) indocyanine fluorophore Cy5.5 conjugated to targeting moieties that recognize CA125. This targeting is expected to accentuate differences between normal and cancerous tissues significantly. The advantage of our approach is that the proposed targeting moieties are smaller in size than antibodies, non-toxic and non-immunogenic and could be selected and produced faster than traditional antibodies. Small size will provide better and faster tissue penetration and would shorten the time between administration of the fluorescent agent and its detection. Application of the proposed approach will facilitate early detection of OC in the high risk group of patients and will increase selectivity of surgical procedures without compromising tumor removal efficiency of the surgery. Survival and quality of life of ovarian cancer patients mostly depends on early detection and effective surgical treatment of the disease. Optical methods for detection of ovarian tumors and their metastasis are essential clinical tools for detection of the disease, surgical eradication and monitoring treatment progress. We will develop a novel class of targeted fluorescent probes that will dramatically increase sensitivity and specificity of optical methods.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government